Random #1
The purpose of this study is to evaluate whether a new medication, Tirzepatide, will help adolescents to lose weight and improve weight related conditions.
Eli Lilly - GPIX
This study will disqualify a patient for taking both and ARB + ACE Inhibitor.
Alnylam ALN-AGT01-008
The purpose of this study is to see if taking a GLP-1 medication named “Orforglipron”, will help reduce pain in patients who suffer from obesity related osteoarthritis of the knee.
Participants must have pain associated with their OA. They must also have a BMI of 27 or higher, they must also be willing to have an X-ray of their knee done, as well as discontinue any paid meds as requested by our site staff.
Eli Lilly GZPT
[BLANK] is a form of atherosclerotic vascular disease affecting arteries outside of the heart, most commonly in the lower extremities. It is characterized by a spectrum of symptoms, including claudication (pain during exercise) and functional impairment. These symptoms result from limited blood flow during exercise and progressive damage to muscle cells.
[BLANK] is a cholesterol‑rich particle produced by the liver. Having high amounts of this can be an independent risk factor for ASCVD.
Lp(A) ; Lipoprotein A.
The purpose of this study is to evaluate how the investigational oral medication, Orforglipron, may help people living with symptomatic Peripheral Artery Disease (PAD).
Participants must be diagnosed with PAD, as well as experience pain, cramping, or heaviness in the calf, thigh, or buttock muscles while walking or exercisin that does stop with rest.
Eli Lilly GZPR
The purpose of this study is to explore a new, more effective way to manage heart failure in individuals who also struggle with obesity and losing weight.
Participants must be diagnosed with class 2,3, or 4 Heart Failure and on treatment for it, have a BMI of 27 or higher, and must meet 1 of 3 categories proving heart disease.
Amgen 20230227
The purpose of this study is to evaluate a new medication, Zilebesiran, which is designed to lower high blood pressure and reduce the risk of heart related complications.
Patients must have established Hypertension, must be on 1 of 3 types of pre-approved Diuretic Meds, as well as either proof of established Cardiovascular Disease... or proof that they are at risk for Cardiovascular Disease.
Alnylam ALN-AGT01-008
[BLANK] is a chronic condition where the body either doesn't use insulin properly (insulin resistance) or doesn't produce enough insulin to maintain normal blood glucose (sugar) levels.
This leads to high blood sugar, which can cause symptoms like increased thirst, frequent urination, and fatigue.
It is often caused by a combination of lifestyle factors like obesity and lack of exercise, along with genetics.
[BLANK] is a chronic condition where the heart can't pump enough oxygen-rich blood to meet the body's needs. It doesn't mean the heart has stopped beating, but rather that it is weakened or stiff, leading to symptoms like fatigue, shortness of breath, and swelling. Causes include heart attack, high blood pressure, and other underlying conditions
Heart Failure
The purpose of this study is to evaluate a new treatment designed to improve the quality of life for people diagnosed with high or elevated lipoprotein.
Participants must have suspected or diagnosed High Lp(a), as well as a presence of ASCVD or Type 2 Diabetes.
[BLANK] is a degenerative joint disease that occurs when the protective cartilage cushioning the ends of your bones wears down over time, causing bones to rub against each other
Osteoarthritis
The purpose of this study is to evaluate a new medication designed to reduce the risk or adverse liver related outcomes, such as cirrhosis, in participants with Liver Disease associated with metabolism - not alcohol consumption.
Participants must have a BMI of 25 or higher. Fatty liver can be tested for at site if your patient is unsure.
Eli Lilly MALO
[BLANK] is when the pressure of blood against your artery walls is consistently too high. Over time, this extra pressure can damage blood vessels and organs like the heart, kidneys, brain, and eyes even if you don’t feel symptoms right away. It’s often called a “silent killer” because it usually has no symptoms until serious damage has occurred.
The purpose of this trial is to see if adding the medications Baxdrostat + Dapagliflozin can better prevent heart failure and cardiovascular death in participants who are at high risk of developing heart failure.
Participants must be diagnosed with Type 2 Diabetes and on treatment for it, have any history of HTN ever, have evidence of cardiovascular disease, as well as one additional risk factor.
AstraZeneca D6973C00001